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Abstract
Introduction Breast cancers of different histology have different
clinical and prognostic features. There are also indications of
differences in aetiology. We therefore evaluated the risk of the
three most common histological subtypes in relation to
menopausal hormone therapy and other breast cancer risk
factors.
Methods We used a population-based case-control study of
breast cancer to evaluate menopausal hormone therapy and
other breast cancer risk factors for risk by histological subtype.
Women aged 50 to 74 years, diagnosed with invasive ductal (n
= 1,888), lobular (n = 308) or tubular (n = 93) breast cancer in
Sweden in 1993 to 1995 were compared with 3,065 age-
frequency matched controls randomly selected from the
population. Unconditional logistic regression was used to
calculate odds ratios (ORs) and 95% confidence intervals (CIs)
for ductal, lobular, and tubular cancer.
Results Women who had used medium potency estrogen alone
were at increased risks of both ductal and lobular cancer.
Medium potency estrogen-progestin was associated with
increased risks for all subtypes, but the estimates for lobular and
tubular cancer were higher compared with ductal cancer. We
found OR 5.6 (95% CI 3.2–9.7) for lobular cancer, OR 6.5
(95% CI 2.8–14.9) for tubular cancer and OR 2.3 (95% CI 1.6–
3.3) for ductal cancer with ≥5 years use of medium potency
estrogen-progestin therapy. Low potency oral estrogen (mainly
estriol) appeared to be associated with an increased risk for
lobular cancer, but the association was strongest for short-term
use. Reproductive and anthropometric factors, smoking, and
past use of oral contraceptives were mostly similarly related to
the risks of the three breast cancer subtypes. Recent alcohol
consumption of > 10 g alcohol/day was associated with
increased risk only for tubular cancer (OR 3.1, 95% CI 1.4–6.8).
Conclusion Menopausal hormone therapy was associated with
increased risks for breast cancer of both ductal and lobular
subtype, and medium potency estrogen-progestin therapy was
more strongly associated with lobular compared with ductal
cancer. We also found medium potency estrogen-progestin
therapy and alcohol to be strongly associated with tubular
cancer. With some exceptions, most other risk factors seemed
to be similarly associated with the three subtypes of breast
cancer.
Introduction
Use of menopausal hormone therapy has been shown to
increase the risk of breast cancer[1], and data indicate that
combined medium potency estrogen-progestin therapy
(mainly estradiol or conjugated estrogens combined with pro-
gestin) is associated with a higher risk for breast cancer than
medium potency estrogen alone therapy [2,3]. The incidence
rate of lobular breast cancer has increased more rapidly than
that of ductal breast cancer during the past 30 years. [4,5],
coinciding with the introduction and rising use of menopausal
hormone therapy. Furthermore, studies from the United States
have rather consistently found medium potency estrogen-pro-Page 1 of 13
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than with ductal breast cancer risk [6-11]. It is not clear, how-
ever, whether use of menopausal hormone therapy also
increases the risk of ductal breast cancer, or whether medium
potency estrogen alone therapy has differential impacts on
lobular and ductal breast cancer risk. Apart from one study
reporting a strong association with menopausal hormone ther-
apy [12], little is known about the aetiology of tubular breast
cancer. Whether low potency oral estrogen (oral estriol with-
out progestin) or local estrogen (cream or pessary, without
progestin) are associated with certain histological subtypes of
breast cancer has, to our knowledge, not been studied before.
Lastly, the influence of other breast cancer risk factors on his-
tological subtypes of breast cancer is not well known [13-17].
We report results on these relationships from a large Swedish
case-control study. The types of estrogens and gestagens
used for menopausal hormone therapy differ between coun-
tries and, to our knowledge, this is the first study outside the
United States to report in detail on these associations.
Materials and methods
Subjects
This study is an extension of a case-control study among all
Swedish residents born in Sweden and aged 50 to 74 years
between 1 October 1993 and 31 March 1995 [18-21]. The
study was approved by the ethical review board at the Karolin-
ska Institute, and by the five ethical review boards in other
regions in Sweden. Women with incident primary invasive
breast cancer were identified via the six Swedish Regional
Cancer Registries. The women were contacted via their doc-
tors and asked for written consent to be approached with a
mailed questionnaire. The study identified 3,979 women with
a diagnosis of invasive breast cancer, of whom 84% (3,345)
participated. The primary reasons for non-participation were
patient's refusal or doctor's refusal because of the patient's
poor health. The mean interval from diagnosis to data collec-
tion was 4.3 months (standard deviation 1.5 months).
Controls were frequency matched by the expected age distri-
bution among cases and identified through the Swedish
National Population Register holding data on national registra-
tion number, name, address, and place of birth of all Swedish
residents. The response rate among controls was 82%
(3,455/4,188). Women previously diagnosed with invasive
cancer (other than non-melanoma skin cancer) were excluded
from the study (112 cases and 91 controls). Menopause was
defined as the age at last menstrual period or age at bilateral
oophorectomy, if one year or more prior to data collection. Pre-
menopausal women (198 cases and 152 controls), women
below the age of 55 years with unknown age at menopause
considered premenopausal (202 cases and 101 controls),
and women with missing information on body mass index
(BMI; 14 cases and 45 controls) or age at first birth (5 cases
and 1 control) were excluded.
In a second phase of the study, we retrieved information about
histology and various other tumour characteristics from the
medical records of all participating cases. Following a decision
of the ethical review board of the University of Lund, written
informed consent to retrieve this information was sought from
cases in that region (n = 563), among whom 58 women did
not provide informed consent. The medical records for 31
study participants could not be found.
Information from the medical records led us to exclude a fur-
ther 58 cases with non-invasive breast cancer, 35 cases with
previous cancer, one case with a cancer diagnosis other than
breast cancer, and 19 cases diagnosed before or after the
study period. The final study comprised 2,643 breast cancer
cases and 3,065 controls.
Data collection
Data on sociodemographic, anthropometric, reproductive and
menstrual factors, use of oral contraceptives, medical history,
lifetime physical activity and smoking habits, as well as recent
(one year before data collection) dietary habits and alcohol
use were collected by means of a postal questionnaire.
Detailed information on use of menopausal hormone therapy,
including timing and type of hormones for each treatment epi-
sode, was also requested and a colour chart displaying all
preparations ever marketed in Sweden was included with the
questionnaire to aid recall. In addition, approximately 50% of
both cases and controls were contacted by telephone to com-
plete missing or ambiguous responses, mainly on use of men-
opausal hormone therapy. Of all eligible controls, 14% did not
return the questionnaire, but agreed to a telephone interview
covering the most important items, including use of menopau-
sal hormone therapy.
We obtained information on tumour histology from the pathol-
ogy report in the medical record. Histology was classified after
the invasive component as ductal (n = 1,888), lobular (n =
308), tubular (≥90% tubular component, n = 93), mixed lob-
ulo-ductal (n = 58), medullary (n = 29), mucinous (n = 61),
papillary (n = 10), adenocarcinoma not otherwise specified (n
= 122), or unspecified tumours (n = 38). Information on histol-
ogy was missing in 36 cases because the medical record was
not identified, or the woman had not had a breast cancer oper-
ation. We analysed ductal, lobular, and tubular cases and all
other cases were excluded from the analyses. Adenocarci-
noma not otherwise specified was not analysed as we consid-
ered it an undefined subtype, and the other histology subtypes
were too few to be analysed separately.
Statistical analyses
We used unconditional logistic regression to estimate odds
ratios (ORs) with associated 95% confidence intervals (95%
CIs) separately for ductal, lobular, and tubular cancer cases
compared with controls. To formally test whether effect esti-
mates were different for lobular or tubular cancer comparedPage 2 of 13
(page number not for citation purposes)
Available online http://breast-cancer-research.com/content/8/1/R11Table 1
Selected characteristics of the study population
Characteristic Controls (n = 3,065) Ductal cancer (n = 1,888) Lobular cancer (n = 308) Tubular cancer (n = 93)
No. (%) No. (%) No. (%) No. (%)
Age (years)
50–54 233 (8) 195 (10) 31 (10) 9 (10)
55–59 582 (19) 431 (23) 70 (23) 20 (22)
60–64 678 (22) 390 (21) 61 (20) 26 (28)
65–69 790 (26) 473 (25) 73 (24) 23 (25)
70–74 782 (26) 399 (21) 73 (24) 15 (16)
Surgical menopause
Yes 125 (4) 85 (5) 11 (4) 5 (5)
Unknown 10 27 5 1
Menopausal symptoms
Yes 1,469 (57) 1,113 (60) 186 (61) 62 (67)
Unknown 477 29 2 1
Socioeconomic status
Blue collar worker 830 (32) 549 (29) 93 (30) 18 (20)
White collar worker 1,412 (54) 1,081 (58) 175 (57) 60 (67)
Other 337 (14) 248 (13) 39 (13) 12 (13)
Unknown 450 10 1 3
Ever use of menopausal 
hormone therapy
Any type 1,185 (39) 891 (47) 170 (55) 55 (59)
Unknown 24 5 1 0
Estrogen (+/- 
progestin)
612 (20) 533 (28) 116 (38) 40 (43)
Estradiol 506 (17) 452 (24) 100 (33) 36 (39)
Conjugated 
estrogens
69 (2) 80 (4) 17 (6) 5 (5)
Other estrogens 19 (0.6) 17 (0.9) 3 (1) 1 (1)
Administration of 
estrogen
Tablets 526 (17) 465 (25) 103 (34) 39 (42)
Patches 123 (4) 114 (6) 18 (6) 4 (4)
Injections 20 (0.7) 12 (0.6) 1 (0.3) 1 (1)Page 3 of 13
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lar cases with ductal cases. For the tests comparing lobular or
tubular cancer with ductal cancer, a two-sided p-value < 0.05
was considered a significant difference.
Use of menopausal hormone therapy was categorized accord-
ing to type as medium potency estrogen alone (mainly estra-
diol or conjugated estrogens), medium potency estrogen with
progestin, progestin alone (without concomitant estrogen),
low potency oral estrogen (oral estriol without progestin), or
local estrogen (cream or pessary, without progestin) for each
treatment episode. Medium potency estrogen-progestin ther-
apy was also classified according to regimen, that is, as
sequential (progestin taken less than 16 days per 28 days) or
continuous use (19 or more days per 28 days). We censored
all exposure after a reference date, defined in cases as date of
diagnosis minus 3 months, and in controls as the date of ques-
tionnaire arrival minus mean time from diagnosis to question-
naire arrival in cases, minus an additional 3 months.
We studied the effect of ever use, duration and recency of use.
Analyses of the associations between use of specific types of
menopausal hormone therapy and the risk of breast cancer
were performed both for non-exclusive use (all users of that
specific therapy), and restricted to exclusive users of that par-
ticular type, with never users of any menopausal hormone ther-
apy as the reference group. No more than five women reported
exclusive current use of progestin alone therapy, so we were
unable to evaluate this therapy. Only 31 women had simulta-
neously used progestin with low potency oral estrogen or local
estrogen, so this combination was not analysed separately,
but these women were excluded from all analyses on exclusive
use.
In the analyses on menopausal hormone therapy, women with
an unknown age at menopause were excluded (296 cases
and 301 controls) to avoid bias leading to underestimation of
the associations as first pointed out by Pike and colleagues
[22].
We adjusted all estimates for age. We also assessed the
potential confounding effects of a range of other variables,
including number of births, age at first birth, age at meno-
pause, surgical menopause (bilateral oophorectomy), meno-
pausal symptoms, BMI (weight(kg)/height (m)2) one year
before data collection, height, socioeconomic status, smoking,
and ever use of medium potency estrogen-progestin therapy.
Confounding was defined as changing the point estimates
more than 10% from the age-adjusted values. Only covariates
confounding the effect of at least one of the exposures in the
same table were included in the models. In addition, age at first
birth and parity were adjusted for each other.
The analyses of the influence of age at menopause on the risk
of different breast cancer subtypes were restricted to women
with a known age at menopause that had not used menopau-
sal hormone therapy apart from local estrogen before meno-
pause in order to reduce confounding. The influence of BMI
one year before data collection and the risks of different breast
cancer subtypes was evaluated only among never users of
menopausal hormone therapy apart from local estrogen – as
BMI and menopausal hormone therapy are known to interact
biologically to cause breast cancer [20]. This interaction was
studied in another approach, where study participants were
cross-classified by their use of medium potency estrogen-pro-
gestin therapy and BMI, and the risks of ductal and lobular
cancer were calculated. Analyses were performed using the
SAS System, version 9.1 (SAS Institute, Carey, NC, USA).
Results
Controls were slightly older than cases (Table 1). Surgical
menopause was equally common among cases and controls.
Menopausal symptoms were slightly more common among
cases than controls. Cases, especially tubular cancer cases,
were more frequently of high socioeconomic status than con-
trols. Ever use of menopausal hormone therapy (all types com-
bined) was more common among cases than controls. Among
users of medium potency estrogen, estradiol (mainly 2 mg
orally/day or 50 µg transdermally/day) was most frequently
used and per oral administration (tablets) was most common.
When progestin was used, testosterone-derived progestins
Progestin (+/- estrogen) 462 (15) 420 (22) 95 (31) 38 (41)
Progesterone 
derived progestin
138 (5) 126 (7) 39 (13) 9 (10)
Testosterone derived 
progestin
371 (12) 353 (19) 79 (26) 35 (38)
Low potency oral 
estrogen
354 (12) 224 (12) 45 (15) 9 (10)
Local estrogen 374 (12) 260 (14) 33 (11) 12 (13)
Table 1 (Continued)
Selected characteristics of the study populationPage 4 of 13
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Menopausal hormone therapy and risk of ductal, lobular and tubular cancer
Controls Ductal cancer Lobular cancer Tubular cancer
No. No. ORa (95%CI) No. ORa (95%CI) No. ORa (95%CI)
Regimen
No use 1,707 903 1.0 (Ref) 121 1.0 (Ref) 37 1.0 (Ref)
Medium potency estrogen alone
Non-exclusive use
Ever 167 154 1.9 (1.5–2.4) 29 2.5 (1.6–3.9) 12 3.5 (1.8–6.9)
Current 72 67 2.0 (1.4–2.8) 10 2.1 (1.0–4.3) 1 0.7 (0.1–5.6)
Exclusive useb
Ever 76 73 2.0 (1.5–2.9) 12 2.4 (1.3–4.6) 1 0.7 (0.1–5.1)
Duration
<5 years 50 40 1.6 (1.0–2.5) 6 1.7 (0.7–4.2) 0 -
≥5 years 22 27 2.9 (1.6–5.2) 4 3.1 (1.0–9.5) 1 2.7 (0.3–21.2)
Recency
Current 31 26 1.6 (1.0–2.8) 6 3.0 (1.2–7.5) 0 -
Past 41 41 2.2 (1.4–3.5) 4 1.5 (0.5–4.2) 1 1.3 (0.2–10.3)
Medium potency estrogen-progestin
Non-exclusive use
Ever 350 320 1.6 (1.3–1.9) 79 3.2c (2.3–4.4) 32 4.1c (2.4–7.0)
Current 222 208 1.7 (1.3–2.1) 43 2.8c (1.8–4.2) 16 3.3 (1.7–6.4)
Exclusive useb
Ever 232 215 1.6 (1.3–2.0) 43 2.7c (1.8–4.0) 16 3.2 (1.6–6.1)
Duration
<5 years 160 137 1.4 (1.1–1.8) 22 1.8 (1.1–3.1) 7 1.9 (0.8–4.7)
≥5 years 62 71 2.3 (1.6–3.3) 21 5.6c (3.2–9.7) 9 6.5c (2.8–14.9)
Recency
Current 155 171 2.0 (1.5–2.5) 36 3.3c (2.1–5.3) 14 4.2c (2.1–8.8)
Past 67 37 1.0 (0.7–1.5) 7 1.6 (0.7–3.6) 2 1.4 (0.3–6.1)
Sequential medium potency estrogen-progestind
Non-exclusive use
Ever 186 199 1.9 (1.5–2.4) 46 3.6c (2.4–5.4) 19 4.5c (2.4–8.3)
Current 88 90 1.8 (1.3–2.4) 12 2.1 (1.1–4.0) 6 2.7 (1.1–7.1)
Exclusive useb
Ever 77 79 1.8 (1.3–2.5) 11 2.1 (1.0–4.2) 5 2.6 (0.9–7.4)
Duration
<5 years 56 63 1.9 (1.3–2.8) 7 1.7 (0.8–4.1) 4 2.8 (0.9–9.0)
≥5 years 15 16 2.1 (1.0–4.3) 3 3.4 (0.9–12.1) 1 2.7 (0.3–21.7)
Recency
Current 33 57 2.9 (1.8–4.6) 7 2.9 (1.2–7.1) 4 4.6 (1.4–15.8)Page 5 of 13
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Continuous medium potency estrogen-progestine
Non-exclusive use
Ever 207 198 1.8 (1.4–2.2) 53 3.7c (2.5–5.4) 20 4.8c (2.6–8.9)
Current 124 92 1.4 (1.0–1.8) 25 2.9c (1.8–4.8) 6 2.3 (0.9–6.0)
Exclusive useb
Ever 114 85 1.4 (1.0–1.9) 22 2.8c (1.6–4.7) 6 2.6 (1.0–6.7)
Duration
<5 years 86 48 1.0 (0.7–1.4) 13 2.0c (1.0–3.8) 2 1.2 (0.3–5.2)
≥5 years 24 30 2.7 (1.5–4.7) 8 5.9 (2.5–14.0) 4 8.2 (2.4–27.5)
Recency
Current 90 68 1.4 (1.0–2.0) 18 2.9c (1.6–5.2) 6 3.3 (1.3–8.8)
Past 20 10 0.8 (0.4–1.8) 3 2.0 (0.6–6.9) 0 -
Low potency oral estrogen
Non-exclusive use
Ever 314 192 1.2 (1.0–1.5) 42 1.9c (1.3–2.8) 9 1.4 (0.7–3.0)
Current 190 113 1.2 (0.9–1.6) 27 2.0c (1.3–3.2) 4 1.0 (0.3–2.9)
Exclusive useb
Ever 192 113 1.2 (0.9–1.5) 27 2.0c (1.3–3.2) 4 1.0 (0.3–2.8)
Duration
<5 years 139 87 1.3 (0.9–1.7) 23 2.3c (1.4–3.8) 3 1.0 (0.3–3.4)
≥5 years 50 25 1.1 (0.6–1.8) 4 1.2 (0.4–3.4) 1 1.0 (0.1–7.7)
Recency
Current 137 72 1.1 (0.8–1.5) 13 1.4 (0.7–2.5) 2 0.7 (0.2–3.1)
Past 52 40 1.6 (1.0–2.4) 14 3.8c (2.0–7.1) 2 1.6 (0.4–6.9)
Local estrogen
Non-exclusive use
Ever 349 226 1.3 (1.0–1.5) 31 1.3 (0.8–1.9) 10 1.3 (0.7–2.8)
Current 229 130 1.1 (0.9–1.4) 13 0.8 (0.4–1.5) 7 1.5 (0.7–3.5)
Exclusive useb
Ever 236 133 1.1 (0.9–1.4) 14 0.8 (0.5–1.5) 7 1.5 (0.6–3.4)
Duration
<5 years 165 90 1.0 (0.8–1.3) 11 0.9 (0.5–1.8) 5 1.5 (0.6–4.0)
≥5 years 62 39 1.3 (0.8–1.9) 2 0.5 (0.1–1.9) 2 1.6 (0.4–7.0)
Recency
Current 168 94 1.1 (0.8–1.4) 10 0.9 (0.4–1.7) 6 1.8 (0.8–4.5)
Past 59 35 1.1 (0.7–1.7) 3 0.7 (0.2–2.2) 1 0.7 (0.1–5.6)
Women with unknown age at menopause were excluded. Recency: Current = last use within 6 months before reference date (see methods for 
definition or reference date); Past = last use > 6 months before reference date. aAdjusted for age, age at first birth, age at menopause and recent 
body mass index (one year before data collection). bUsers of more than one kind of menopausal hormone therapy excluded. cStatistically 
significant difference compared with the estimate for ductal cancer. dSequential estrogen-progestin: progestin included <16 days per 28 days. 
eContinuous estrogen-progestin: progestin included > 19 days per 28 days. CI, confidence interval; OR, odds ratio; Ref, reference category.
Table 2 (Continued)
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if added continuously; and either 250 µg levonorgestrel/day or
1 mg norethisterone acetate/day in 10 of 28 days if added
cyclically). Use of low potency oral estrogen therapy consti-
tuted almost principally 1 mg estriol per day and was more
common among lobular cases than other cases and controls,
and local estrogen therapy consisted of cream or pessary con-
taining estradiol or estriol. Local estrogen therapy was equally
common among cases and controls.
Medium potency estrogen alone
Use of medium potency estrogen alone was similarly associ-
ated with increased risks of ductal and lobular cancer (Table
2). Due to few cases, tubular cancer was not possible to eval-
uate. Exclusive ever use of medium potency estrogen alone
was similarly associated with the risks of ductal (OR 2.0, 95%
CI 1.5–2.9) and lobular (OR 2.4, 95% CI 1.3–4.6) breast can-
cer. Use for more than five years entailed ORs of 2.9 (95% CI
1.6–5.2) and 3.1 (95% CI 1.0–9.5) for ductal and lobular
breast cancer, respectively (Table 2). Ductal and lobular can-
cers were both associated with current use, and ductal cancer
in addition with past use, but without significant differences
between ductal and lobular cancer.
Medium potency estrogen plus progestin
Use of medium potency estrogen-progestin was associated
with increased risks of all three subtypes of breast cancer, with
the highest risks among ≥5 years and current exclusive use
(Table 2). These risks were significantly higher among lobular
and tubular cancer compared with ductal cancer. Women who
used medium potency estrogen-progestin for ≥5 years (of
whom > 80% were current users) had an OR of 2.3 for ductal
cancer (95% CI 1.6–3.3), OR 5.6 for lobular cancer (95% CI
3.2–9.7), and OR 6.5 (95% CI 2.8–14.9) for tubular cancer
compared with those who never used menopausal hormone
therapy (Table 2). Among past users, no clear association with
any cancer subtype was discerned.
Sequential and continuous medium potency estrogen-
progestin
Non-exclusive users of both sequential and continuous
medium potency estrogen-progestin had a median duration
treatment of four years, compared with two years for exclusive
users (data not shown). This was reflected in the higher point
estimates for non-exclusive compared with exclusive ever use
for lobular and tubular breast cancer (Table 2). Exclusive use
of sequential medium potency estrogen-progestin therapy
was not significantly differently associated with ductal, lobular
or tubular cancer. Exclusive use of continuous medium
potency estrogen-progestin therapy, on the other hand, was
significantly more strongly associated with lobular compared
with ductal cancer, when measured as ever use, <5 years use,
and current use. Continuous use ≥5 years was associated
with high point estimates for lobular (OR 5.9, 95% CI 2.5–
14.0) and tubular (OR 8.2, 95% CI 2.4–27.5) cancer, but not
significantly different from ductal cancer (OR 2.7, 85% CI
1.5–4.7). For lobular cancer the different risk estimates for
exclusive ever use of continuous versus sequential use did not
reach statistical significance (p = 0.36).
Low potency estrogen
Non-exclusive and exclusive ever use of low potency oral
estrogen was associated with an increased risk for lobular
(OR 2.0, 95% CI 1.3–3.2) but not ductal (OR 1.2, 95% CI
0.9–1.5) or tubular (OR 1.0, 95% CI 0.3–2.8) breast cancer
(Table 2). The increased risk was confined to <5 years of use
and past users.
Local estrogen
We found no associations between non-exclusive or exclusive
use of local low potency estrogen therapy and either ductal or
lobular breast cancer (Table 2). The estimates for tubular can-
cer were non-significantly above unity, with no trend of
increased estimates for longer duration.
Reproductive factors
The risks associated with parity, age at menarche and age at
menopause did not vary significantly between the three histo-
logical subtypes (Table 3). Increasing number of births was
associated with a decreased risk of ductal but not of lobular
cancer. Age at first birth was slightly more associated with lob-
ular than with ductal cancer, but the difference was not signif-
icant.
Anthropometric factors
Height was similarly associated with the three subtypes.
Recent BMI and adult weight gain, evaluated among never
users of menopausal hormone therapy apart from local estro-
gen, were associated with similar ORs for ductal and lobular
cancer (Table 3). The association between recent BMI and
tubular cancer was close to unity, but not statistically different
from the estimates for ductal cancer.
Other factors
Having a mother or sister with breast cancer seemed more
strongly associated with lobular (OR 2.4, 95% CI 1.8–3.4)
than with ductal (OR 1.8, 95% CI 1.5–2.2) breast cancer (p
for heterogeneity = 0.06). Previous operation due to benign
breast disease was associated with slightly higher risk for lob-
ular (OR 1.9, 95% CI 1.4–2.6) compared with ductal (OR 1.5,
95% CI 1.2–1.8) cancer. The OR for tubular cancer was near
unity, but not statistically different from ductal cancer. Use of
oral contraceptives (99% of all users stopped v5 years before
the reference date) was not associated with any of the three
histological subtypes of breast cancer among these postmen-
opausal women (Table 3). Recent high alcohol consumption
was associated with tubular breast cancer (OR for ≥10 g/day
3.1, 95% CI 1.4–6.8). For lobular cancer a tendency of higher
ORs with increasing alcohol consumption was seen, but no
category had a significantly increased OR (Table 3). We foundPage 7 of 13
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Various breast cancer risk factors and risk of ductal, lobular and tubular breast cancer
Controls Ductal cancer Lobular cancer Tubular cancer
No. No. ORa (95%CI) ORa (95%CI) No. ORa (95%CI)
Factor
Parous
Nulliparous 337 292 1.0 (Ref) 40 1.0 (Ref) 10 1.0 (Ref)
Parous 2,643 1,561 0.7 (0.6–0.8) 258 0.8 (0.6–1.2) 81 1.0 (0.5–2.0)
No of birthsb
1 558 416 1.0 (Ref) 47 1.0 (Ref) 21 1.0 (Ref)
2 1073 690 0.9 (0.7–1.0) 126 1.5c (1.0–2.1) 36 0.9 (0.5–1.6)
3 630 318 0.7 (0.6–0.9) 58 1.3c (0.8–1.9) 19 0.9 (0.5–1.8)
≥4 382 137 0.6 (0.4–0.7) 27 1.1c (0.7–1.9) 5 0.5 (0.2–1.3)
Age at first birth (years)b
<20 305 143 0.9 (0.7–1.1) 20 0.7 (0.4–1.1) 9 1.3 (0.6–2.9)
20–24 1,125 600 1.0 (Ref) 106 1.0 (Ref) 25 1.0 (Ref)
25–29 836 526 1.1 (1.0–1.3) 79 1.0 (0.7–1.4) 29 1.5 (0.9–2.6)
≥30 377 292 1.3 (1.1–1.6) 53 1.6 (1.1–2.3) 18 1.9 (1.0–3.7)
Age at menarche (years)d
<12 164 134 1.3 (1.0–1.7) 23 1.3 (0.8–2.1) 4 0.7 (0.2–1.9)
12–13 1,155 702 1.0 (Ref) 117 1.0 (Ref) 38 1.0 (Ref)
14–15 1,161 723 1.1 (0.9–1.2) 109 1.0 (0.7–1.3) 43 1.2 (0.7–1.8)
≥16 236 113 0.8 (0.6–1.0) 23 1.0 (0.6–1.5) 3 0.4 (0.1–1.2)
Age at menopause (years)e
<45 328 144 0.7 (0.5–0.8) 22 0.7 (0.4–1.1) 4 0.4 (0.1–1.1)
45–49 658 368 0.8 (0.7–1.0) 68 1.0 (0.8–1.4) 24 1.2 (0.7–2.0)
50–54 1,236 805 1.0 (Ref) 121 1.0 (Ref) 37 1.0 (Ref)
≥55 268 174 1.0 (0.8–1.3) 27 1.1 (0.7–1.7) 3 0.4 (0.1–1.2)
Height (cm)
<160 652 361 1.0 (Ref) 46 1.0 (Ref) 16 1.0 (Ref)
160–164 1,012 593 1.0 (0.9–1.2) 110 1.5c (1.1–2.2) 27 1.0 (0.5–1.8)
165–169 880 555 1.1 (0.9–1.3) 86 1.3 (0.9–1.9) 27 1.1 (0.6–2.1)
≥170 436 344 1.3 (1.1–1.6) 57 1.7 (1.1–2.6) 21 1.7 (0.9–3.3)
Recent BMI (kg/m2)f
<22.2 430 165 1.0 (Ref) 26 1.0 (Ref) 9 1.0 (Ref)
22.2–<24.2 423 214 1.3 (1.0–1.7) 25 1.0 (0.6–1.7) 10 1.1 (0.4–2.8)
24.2–<26.0 427 217 1.3 (1.0–1.7) 21 0.8 (0.5–1.5) 9 1.0 (0.4–2.5)
26.0–<28.5 420 251 1.6 (1.2–2.0) 39 1.6 (0.9–2.6) 9 1.0 (0.4–2.6)
≥28..5 430 301 1.9 (1.5–2.3) 41 1.6 (1.0–2.6) 9 1.0 (0.4–2.6)
Adult weight gain (kg)d,f,g
<0 159 64 0.8 (0.6–1.1) 11 0.9 (0.5–1.9) 4 0.8 (0.3–2.4)Page 8 of 13
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and ductal cancer. Recent smoking was borderline associated
with risk of ductal cancer (OR 1.2, 95% CI 1.0–1.4), and the
OR for tubular cancer was significantly lower compared with
ductal cancer (OR 0.8, 95% CI 0.5–1.2) but not significantly
different compared with controls (Table 3).
Interaction between medium potency estrogen-
progestin use and BMI
We stratified exclusive ever use of medium potency estrogen-
progestin into three categories of BMI (Table 4). The
increased risk for both ductal and lobular breast cancer with
medium potency estrogen-progestin use seemed to be con-
fined to women with BMI ≤27. Among women with BMI < 22,
exclusive ever users of medium potency estrogen-progestin
had OR 2.0 (95% CI 1.2–3.3) for ductal cancer and OR 3.4
(95%CI1.4–8.3) for lobular cancer compared with never
users of menopausal hormone therapy
Discussion
We found increased risks of both ductal and lobular breast
cancer among women who used medium potency estrogen
alone or in combination with progestin. Medium potency estro-
gen-progestin therapy, but not medium potency estrogen
alone therapy, was significantly more strongly related to lobu-
lar than to ductal breast cancer. The risk with medium potency
estrogen-progestin therapy was confined to women with a
BMI ≤27. We found a stronger association with medium
potency estrogen-progestin therapy for tubular cancer com-
pared with ductal cancer. For most other risk factors, we found
no strong variations in the associations with the three sub-
types, but some indications of difference for parity, BMI, family
history and recent alcohol consumption.
0–9.5 459 242 1.0 (Ref) 34 1.0 (Ref) 15 1.0 (Ref)
10–19.5 534 349 1.2 (1.0–1.5) 44 1.1 (0.7–1.8) 13 0.7 (0.3–1.6)
20–29.5 226 171 1.5 (1.1–1.9) 21 1.2 (0.7–2.2) 6 0.8 (0.3–2.2)
≥30 99 75 1.5 (1.1–2.1) 13 1.8 (0.9–3.5) 6 2.0 (0.7–5.3)
Mother or sister with breast cancerd
No 2,294 1,530 1.0 (Ref) 237 1.0 (Ref) 73 1.0 (Ref)
Yes 233 278 1.8 (1.5–2.2) 57 2.4 (1.8–3.4) 15 2.2 (1.2–3.9)
Operated due to benign breast diseased
No 2,315 1,590 1.0 (Ref) 245 1.0 (Ref) 82 1.0 (Ref)
Yes 242 253 1.5 (1.2–1.8) 53 1.9 (1.4–2.6) 9 0.9 (0.4–1.8)
Oral contraceptive used
No use 2,030 1,237 1.0 (Ref) 198 1.0 (Ref) 55 1.0 (Ref)
Duration
<5 years 470 302 0.9 (0.7–1.0) 40 0.6 (0.4–0.9) 23 1.3 (0.7–2.2)
≥5 years 331 215 0.9 (0.7–1.1) 42 0.9 (0.6–1.4) 13 1.0 (0.5–1.9)
Recent alcohol consumption (g/day)d
No alcohol 1,108 762 1.0 (Ref) 111 1.0 (Ref) 28 1.0 (Ref)
<5 905 674 1.0 (0.9–1.2) 101 1.0 (0.8–1.4) 34 1.2 (0.7–2.1)
≥5–10 210 171 1.1 (0.9–1.4) 32 1.3 (0.9–2.1) 12 1.8 (0.9–3.6)
>10 100 72 1.0 (0.7–1.4) 19 1.6 (0.9–2.8) 10 3.1c (1.4–6.8)
Recent smokingd
No 2,212 1,442 1.0 (Ref) 229 1.0 (Ref) 63 1.0 (Ref)
Yes 696 408 1.2 (1.0–1.4) 68 1.1 (0.8–1.5) 28 0.8c (0.5–1.2)
Recent = one year before data collection. aAdjusted for age, and where applicable also for estrogen-progestin use (ever/never). bNumber of births 
and age at first birth were adjusted for each other. cStatistically significant difference compared with the estimate for ductal cancer. dSome cases 
and controls excluded due to missing information. eWomen with unknown age at menopause and women using menopausal hormone therapy 
apart from local estrogen before menopause excluded. fWomen ever menopausal hormone therapy apart from local estrogen excluded. gWeight 
gain from 18 years of age to one year before data collection. BMI, body mass index; CI, confidence interval; OR, odds ratio; Ref, reference 
category.
Table 3 (Continued)
Various breast cancer risk factors and risk of ductal, lobular and tubular breast cancerPage 9 of 13
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alone therapy to be associated only with lobular cancer
[6,10,11], while others failed to find any association with either
ductal or lobular breast cancer [8,23]. In contrast to these
results, we found an increased risk for both subtypes of cancer
with use of medium potency estrogen alone therapy. Schairer
and colleagues [2] reported increased risk of ductal cancer
with medium potency estrogen alone therapy among lean, but
not obese women. BMI is known to interact biologically with
estrogen therapy, thereby affecting the association of estro-
gen with breast cancer risk, shown for example in the Million
Women Study [3]. A high average BMI is thus a possible
explanation for the lack of increased breast cancer risk with
conjugated estrogen alone found in the Women's Health Initi-
ative study [24].
Our finding of a stronger association between use of medium
potency estrogen-progestin therapy and the risk of lobular
compared with ductal breast cancer is consistent with pub-
lished results from all previous studies [6-11] except one [23].
In contrast, the increased risk also for ductal cancer after use
of medium potency estrogen-progestin therapy in our data
corroborates some [9,10,23], but not all [6,8,11], published
studies. One possible explanation for our stronger associa-
tions between medium potency estrogen with or without pro-
gestin therapy and both ductal and lobular cancer compared
with others could be differences regarding the hormones used
in our study and in the United States. In our study, estradiol
and higher dose testosterone-derived progestins were most
commonly used, in contrast to mainly conjugated estrogens
and lower dose progesterone-derived progestins in the United
States [25]. Previously published results from our case control
study showed that testosterone-derived progestins were more
strongly related to breast cancer than progesterone-derived
progestins. [20].
Two Scandinavian prospective cohort studies have analysed
menopausal and subsequent risk of histological subtypes of
breast cancer [12,26]. Both found higher risks for lobular com-
pared with ductal cancer, but only Tjønneland and colleagues
found an increased risk also for ductal cancer.
Newcomer and colleagues [11] reported tubular cancer to
make up around 1% of diagnosed breast cancer cases in their
study. They found increased point estimates for tubular cancer
with estrogen alone and past use of estrogen-progestin, but
the power was low. Interestingly, a Swedish cohort study [12]
reported 10 tubular cases out of 131 invasive breast cancers,
and use of menopausal hormone therapy (unspecified) was
associated with a relative risk of 4.81 (95% CI 1.37–16.8) for
tubular cancer. Gapstur and colleagues [27] grouped tumours
said to be of favourable histology together (22% were tubular),
and reported an association with menopausal hormone ther-
apy. We defined histology according to the pathology report,
and found 3.5% of invasive cancers to be purely tubular.
Cases with mixed tubuloductal histology were classified as
ductal. Our finding of a strong association between medium
potency estrogen-progestin therapy and tubular cancer is
interesting as menopausal hormone therapy has been associ-
ated with low grade tumours [12,28], and tubular cancers are
known to have an excellent prognosis. [29]. Studies pooling
data from several centres might shed further light on the risk
factor patterns in this relatively rare form of breast cancer.
Three studies have reported on the impact of sequential ver-
sus continuous estrogen-progestin therapy on ductal and lob-
ular breast cancer risk. In accordance with our results, Chen
and colleagues [7] and Daling and colleagues [8] found non-
significantly higher risks for lobular cancer after use of contin-
uous than after sequential therapy whereas Li and colleagues
[10] found no differences.
To our knowledge, this is the first study to report on the risk of
different histological subtypes of breast cancer after use of
low potency oral estrogen or local estrogen therapy. These
therapies are rather common in Sweden, and the indications
mainly include local vaginal symptoms and urinary tract infec-
tions. Our finding of a significantly increased risk for lobular
cancer among women who used low potency oral estrogen is
noteworthy, and tentatively important with regard to the biolog-
ical mechanisms of breast carcinogenesis. However, this
result must be interpreted cautiously since the pattern of asso-
ciation according to duration and recency of use is contradic-
tory to what is seen with other types of hormone therapy. Oral
estriol is quickly metabolised, so the estrogenic effect of one
dose is short-term [30], but it does have systemic effects [31],
and oral estriol has been associated with increased risk for
endometrial cancer [32]. Locally administered estrogens also
have systemic effects [30], but were not found to be associ-
ated with any of the subtypes of breast cancer in our study.
Few studies have addressed whether risk factors for breast
cancer other than menopausal hormone therapy are differen-
tially associated with the risks of ductal and lobular breast can-
cer. Age at first birth was non-significantly more strongly
associated with lobular than ductal breast cancer in our study
as well as in three [15,16,33] of four [17] previous studies.
Increasing number of births seemed slightly more related to
ductal compared with lobular cancer in our study, supported
by two studies [16,33], whereas two studies found no differ-
ences at all [15,17].
We found no association at all between at least 5 years use of
oral contraceptives and ductal, lobular or tubular cancer, but
only 1% of our postmenopausal participants had last use of
oral contraceptives within 5 years. Newcomer and colleagues
[34] found an association with lobular cancer for users with <5
years since last use, whereas Li and colleagues [17] reported
a borderline association between ≥5 years use of oral contra-Page 10 of 13
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women aged at least 65 years.
The tentatively stronger association between a positive family
history of breast cancer and lobular compared with ductal
breast cancer is supported by others [13,15,35] but not by a
recent Swedish register-based study [36]. Lobular cancers
are more often bilateral [37], and it could be that genetic deter-
minants are more important in the aetiology of lobular than
ductal breast cancer. Li and colleagues [38] have previously
reported a significant association between alcohol consump-
tion and lobular, but not ductal, breast cancer. We had a lower
median consumption of alcohol in our study, but our point esti-
mates give weak support to their finding. In addition, we found
alcohol to be strongly associated with tubular cancer, with
increasing trend over categories, a finding previously not
reported in the literature.
Our study is population-based and large with high response
rates (84% for cases and 82% for controls), and detailed infor-
mation on use of menopasual hormone therapy and on other
breast cancer risk factors. Still, for lobular and even more for
tubular cancer, the number of cases is small, and chance var-
iation may play an important role. Another possible limitation is
that exposure information was self-reported and collected ret-
rospectively. We cannot rule out the possibility that some
women have reported use of medium potency estrogen alone
while they actually have used medium potency estrogen-pro-
gestin. Such misclassification would possibly explain our
strong associations between medium potency estrogen alone
therapy and breast cancer, but the similar risks for both ductal
and lobular cancer differ from what we found for medium
potency estrogen-progestin therapy. Also, the concordance
between self-reported use of menopausal hormone therapy
and information from medical records has been shown to be
satisfactorily high [39,40], and we used a colour chart of all
preparations ever marketed in Sweden to aid recall. As in all
retrospective studies, recall bias is of concern with regard to
the validity of our results. Reassuringly, use of sequential and
continuous combined medium potency estrogen-progestin
were demonstrated to have opposite impacts on the risk of
endometrial cancer in a parallel study using the same set of
controls [41]. Regarding the case/case comparisons, recall
differences due to different histological type is unlikely.
Another limitation is that several pathologists at different labo-
ratories did the histological classifications, which may have
resulted in non-differential misclassification, possibly diluting
the associations.
Many risks are assessed in this study, but we believe it is more
relevant to discuss the results in relation to previous results
and biological credibility than to adjust for multiple compari-
sons in the statistical analyses.
Conclusion
Most risk factors seem to affect ductal, lobular and tubular
breast cancer similarly, but there is accumulating evidence for
medium potency estrogen-progestin therapy as a stronger risk
factor for lobular than ductal breast cancer. We also found sig-
nificant associations between medium potency estrogen alone
therapy and both ductal and lobular cancer, and between
medium potency estrogen-progestin therapy and ductal
breast cancer. Our findings of an association between low
potency oral estrogen and lobular breast cancer, as well as the
strong associations between tubular cancer and both medium
potency estrogen-progestin therapy and alcohol intake is nota-
ble but has yet to be confirmed or refuted by other studies.
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